21Shares Files S-1 for Injective (INJ) Spot ETF, Eyes Staking Rewards

TL;DR

**This 21Shares Injective ETF is a speculative bet on INJ's price, but the uncertain staking rewards make it a cautious 'wait and see' for now.**

AI Summary

21Shares Injective ETF (the "Trust") filed an S-1 registration statement on October 20, 2025, to launch an exchange-traded fund tracking the performance of INJ tokens, the native digital asset of the Injective blockchain. The Trust's investment objective is to track the CME CF Injective-Dollar US Settlement Price, adjusted for expenses, and potentially reflect rewards from staking a portion of its INJ. The Sponsor, 21Shares US LLC, has not yet determined if staking can be conducted as a public trust, but is exploring options including third-party staking service providers and Liquid Staking Tokens. The Trust will hold INJ, with Coinbase Custody Trust Company, LLC and BitGo Trust Company, Inc. serving as INJ Custodians. The Sponsor, as Audit Seed Investor, purchased 2 Seed Creation Baskets for $100.00, which were later redeemed. An Initial Seed Creation Investor is expected to acquire initial seed creation baskets for an undisclosed amount, with proceeds used to purchase INJ. The Trust is structured as a passive investment vehicle, not utilizing leverage or derivatives, and is not registered under the Investment Company Act of 1940, nor regulated by the CFTC as a commodity pool.

Why It Matters

This S-1 filing by 21Shares signals a significant step towards mainstream adoption for the Injective blockchain's native token, INJ, by offering an accessible ETF product to a broader investor base. For investors, it provides a regulated avenue to gain exposure to INJ's price movements without directly holding the cryptocurrency, potentially increasing liquidity and demand for INJ. However, the competitive landscape for crypto ETFs is intensifying, and 21Shares will need to differentiate its offering, especially given the uncertainty around staking rewards. Employees and customers of Injective could see increased network activity and value if the ETF successfully attracts capital, while the broader market watches for regulatory approvals and the performance of such specialized crypto ETFs.

Risk Assessment

Risk Level: high — The S-1 explicitly states, "AN INVESTMENT IN THE TRUST INVOLVES SIGNIFICANT RISKS AND MAY NOT BE SUITABLE FOR SHAREHOLDERS WHO ARE NOT IN A POSITION TO ACCEPT MORE RISK THAN MAY BE INVOLVED WITH EXCHANGE-TRADED PRODUCTS THAT DO NOT HOLD INJ. THE SHARES ARE SPECULATIVE SECURITIES. THEIR PURCHASE INVOLVES A HIGH DEGREE OF RISK AND YOU COULD LOSE YOUR ENTIRE INVESTMENT." This, coupled with the uncertainty surrounding the ability to conduct staking activities without undue legal, regulatory, or tax risk, indicates a high-risk investment.

Analyst Insight

Investors should approach the 21Shares Injective ETF with extreme caution, recognizing the high degree of risk associated with speculative digital assets. Monitor regulatory developments regarding staking and the Trust's ability to implement it, as this could significantly impact potential returns. Consider this a long-term, high-risk allocation, if at all, and only after a thorough review of the 'Risk Factors' section starting on page 18 of the prospectus.

Financial Highlights

debt To Equity

0.0

revenue

$0.00

operating Margin

N/A

total Assets

$0.00

total Debt

$0.00

net Income

$0.00

eps

$0.00

gross Margin

N/A

cash Position

$0.00

revenue Growth

N/A

Key Numbers

• $100.00 — Total proceeds from Seed Creation Baskets (Generated from the sale of 2 Shares at $50.00 each by the Sponsor as Audit Seed Investor.)
• 2 — Number of Seed Creation Baskets (Purchased by the Sponsor as Audit Seed Investor.)
• $50.00 — Per-Share price of Seed Creation Baskets (Price at which the Sponsor purchased Seed Creation Baskets.)
• 2025-10-20T00:00:00.000Z — Filing Date (Date the S-1 registration statement was filed with the SEC.)

Key Players & Entities

• 21Shares Injective ETF (company) — Registrant and exchange-traded fund
• 21Shares US LLC (company) — Sponsor of the Trust
• INJ (dollar_amount) — Native digital asset of the Injective blockchain
• Coinbase Custody Trust Company, LLC (company) — INJ Custodian for the Trust
• BitGo Trust Company, Inc. (company) — INJ Custodian for the Trust
• Russell Barlow (person) — Agent for service for 21Shares US LLC
• Allison M. Fumai, Esq. (person) — Legal counsel from Dechert LLP
• Anna Tomczyk, Esq. (person) — Legal counsel from Dechert LLP
• Neel Maitra, Esq. (person) — Legal counsel from Dechert LLP
• Securities and Exchange Commission (regulator) — Regulatory body for the S-1 filing

FAQ

Risk Factors

• Regulation of INJ and Injective Markets [high — regulatory]: The regulatory landscape for digital assets, including INJ, is evolving and uncertain. Changes in regulations could impact the Trust's ability to hold, custody, or offer shares related to INJ, potentially affecting its investment objective and operations. The filing does not specify which regulatory bodies will oversee INJ or the Trust.
• Volatility of INJ Prices [high — market]: The Trust's performance is directly tied to the price of INJ. The price of INJ is subject to significant volatility due to market sentiment, technological developments, regulatory actions, and other factors, which could lead to substantial fluctuations in the Trust's Net Asset Value (NAV).
• Custody and Security Risks [high — operational]: The Trust will rely on third-party custodians, Coinbase Custody Trust Company, LLC and BitGo Trust Company, Inc., for the safekeeping of its INJ assets. Any failure, breach, or insolvency of these custodians could result in the loss of the Trust's INJ holdings, directly impacting its ability to track the INJ price.
• Staking Risks and Uncertainty [medium — operational]: The Trust is exploring staking INJ to potentially reflect rewards, but it is uncertain if this can be conducted as a public trust. Risks include the selection of third-party staking providers, the security of Liquid Staking Tokens, and potential regulatory implications of staking activities.
• NAV Determination Accuracy [medium — financial]: The Trust's NAV is determined based on the CME CF Injective-Dollar US Settlement Price. Inaccurate or delayed pricing data, or issues with the calculation methodology, could lead to discrepancies between the Trust's NAV and the actual market value of its INJ holdings.
• Audit Seed/Initial Seed Investor Dependence [low — legal]: The Trust's initial capitalization relies on the Audit Seed Investor and an Initial Seed Creation Investor. Any issues with these investors acquiring or redeeming seed creation baskets could delay or prevent the Trust's launch and initial INJ acquisition.

Industry Context

The digital asset ETF market is rapidly expanding, with increasing institutional interest in providing regulated access to cryptocurrencies. Competitors like Grayscale, BlackRock, and others are launching or seeking to launch similar products for various digital assets. The Injective ecosystem itself is focused on decentralized finance (DeFi) applications, particularly derivatives trading, positioning INJ within a niche but growing segment of the crypto market.

Regulatory Implications

The filing highlights the evolving and uncertain regulatory landscape for digital assets in the US. The Trust's structure and operations, particularly regarding INJ custody and potential staking, will be subject to scrutiny. The lack of specific regulatory classification (e.g., under the Investment Company Act of 1940 or CFTC oversight) suggests a reliance on existing frameworks and a potential for future regulatory changes to impact the ETF.

What Investors Should Do

1. Review the S-1 filing thoroughly for detailed risk disclosures.
2. Monitor the SEC's review process and any subsequent amendments to the S-1.
3. Assess the competitive landscape of digital asset ETFs.
4. Evaluate the sponsor's (21Shares) expertise and track record in managing digital asset investment products.

Key Dates

• 2025-10-20: S-1 Registration Statement Filing — Marks the formal initiation of the process to launch the 21Shares Injective ETF, signaling the sponsor's intent to offer shares to the public.

Glossary

S-1 Registration Statement

A form filed with the U.S. Securities and Exchange Commission (SEC) by companies planning to offer securities to the public. It provides detailed information about the company's business, financial condition, and the securities being offered. (This is the foundational document for the ETF's launch, containing all disclosures required by the SEC for public offering.)

INJ

The native digital asset of the Injective blockchain, used for governance, transaction fees, and staking within the Injective ecosystem. (The ETF's primary underlying asset; its performance and regulatory status directly impact the ETF's value.)

CME CF Injective-Dollar US Settlement Price

A benchmark price for INJ, likely calculated by CME Group and CF Benchmarks, used to determine the settlement value of INJ for financial contracts or, in this case, the ETF's Net Asset Value. (This price will be the benchmark for the ETF's investment objective, aiming to track it closely.)

Seed Creation Basket

A unit of creation for the ETF, consisting of a specified amount of the underlying asset (INJ) and/or cash, used by authorized participants to create or redeem ETF shares. (The initial purchase and redemption of these baskets by seed investors are crucial for the ETF's initial funding and INJ acquisition.)

Net Asset Value (NAV)

The per-share market value of an ETF, calculated by taking the total value of its assets, subtracting liabilities, and dividing by the number of outstanding shares. (The ETF aims to track the CME CF Injective-Dollar US Settlement Price, which will influence its NAV calculation.)

Staking

The process of actively participating in transaction validation (similar to mining) on a Proof-of-Stake (PoS) blockchain. Stakers lock up their crypto assets to help secure the network and are rewarded for their contribution. (The Trust is exploring staking INJ to potentially generate additional yield, which could impact its overall returns.)

Liquid Staking Token

A token representing staked assets that can still be traded or used in other DeFi applications, allowing users to earn staking rewards while maintaining liquidity. (One of the potential methods the Trust is considering for conducting staking activities.)

Year-Over-Year Comparison

This is the initial S-1 filing for the 21Shares Injective ETF, filed on October 20, 2025. As such, there is no prior filing to compare key metrics against. Financial highlights such as revenue, net income, and margins are not yet applicable as the ETF has not launched or commenced operations. The filing primarily serves to outline the proposed structure, investment objective, and associated risks of the new fund.

Key Financial Figures

• $50.00 — rising 2 Shares at a per-Share price of $50.00 as described in “Audit Seed/Initi
• $100.00 — ale of these Seed Creation Baskets were $100.00. Delivery of the Seed Creation Baskets

Filing Documents

• ea0261536-s1_21shares.htm (S-1) — 1175KB
• ea026153601ex-fee_21shares.htm (EX-FILING FEES) — 12KB
• 0001213900-25-100111.txt ( ) — 1296KB
• ea026153601ex-fee_21shares_htm.xml (XML) — 3KB

RISK FACTORS

RISK FACTORS 18 INJ, INJ MARKETS AND REGULATION OF INJ 72 THE TRUST AND INJ PRICES 77 NET ASSET VALUE DETERMINATIONS 81 ADDITIONAL INFORMATION ABOUT THE TRUST 84 THE TRUST’S SERVICE PROVIDERS 88 CUSTODY OF THE TRUST’S ASSETS 90 PRIME BROKER 94 FORM OF SHARES 99 TRANSFER OF SHARES 99 AUDIT SEED/INITIAL SEED CREATION INVESTOR 100 PLAN OF DISTRIBUTION 100 CREATION AND REDEMPTION OF SHARES 102

USE OF PROCEEDS

USE OF PROCEEDS 109 109 CONFLICTS OF INTEREST 110 DUTIES OF THE SPONSOR 112 LIABILITY AND INDEMNIFICATION 114 PROVISIONS OF LAW 116 MANAGEMENT; VOTING BY SHAREHOLDERS 116 BOOKS AND RECORDS 117 118 FISCAL YEAR 118 GOVERNING LAW; CONSENT TO DELAWARE JURISDICTION 118 LEGAL MATTERS 118 EXPERTS 118 OTHER MATERIAL CONTRACTS 119 UNITED STATES FEDERAL INCOME TAX CONSEQUENCES 120 PURCHASES BY EMPLOYEE BENEFIT PLANS 125 INFORMATION YOU SHOULD KNOW 126 SUMMARY OF PROMOTIONAL AND SALES MATERIAL 126 INTELLECTUAL PROPERTY 127 WHERE YOU CAN FIND MORE INFORMATION 127 PRIVACY POLICY 128 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM F-2 APPENDIX A A-1

INFORMATION NOT REQUIRED IN PROSPECTUS

PART II INFORMATION NOT REQUIRED IN PROSPECTUS II-1 i This Prospectus contains information you should consider when making an investment decision about the Shares of the Trust. You may rely on the information contained in this Prospectus. The Trust and the Sponsor have not authorized any person to provide you with different information and, if anyone provides you with different or inconsistent information, you should not rely on it. This Prospectus is not an offer to sell the Shares in any jurisdiction where the offer or sale of the Shares is not permitted. The Shares of the Trust are not registered for public sale in any jurisdiction other than the United States. Until 25 calendar days after the date of this Prospectus, all dealers effecting transactions in the Shares, whether or not participating in this offering, may be required to deliver a prospectus. This requirement is in addition to the dealer’s obligation to deliver a prospectus when acting as underwriters and with respect to unsold allotments or subscriptions. REGARDING FORWARD-LOOKING STATEMENTS This Prospectus includes “forward-looking by terminology such as “may,” “will,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or the negative of these terms or other comparable terminology. All statements (other than statements of historical fact) included in this Prospectus that address activities, events or developments that will or may occur in the future, including such matters as movements in the digital asset markets and indexes that track such movements, the Trust’s operations, the Sponsor’s plans and references to the Trust’s future success

View Full Filing

View this S-1 filing on SEC EDGAR